Treprostinil Sodium CAS NO 289480-64-4 Inquire about Treprostinil Sodium

Tecoland supplies Treprostinil Sodium bulk active pharmaceutical ingredient (API) to the pharmaceutical industry. Our Treprostinil Sodium is manufactured by cGMP compliant facility. Welcome to contact us for further details including current DMF status for the product and up to date regulatory status of the manufacturing facility. We look forward to assisting you with your research and development projects.

What is Treprostinil?

Treprostinil (marketed under the trade names Remodulin for infusion and Tyvaso for inhalation) is a vasodilator that is used for the treatment of pulmonary arterial hypertension. Treprostinil is a synthetic analog of prostacyclin (PGI2).

Medical uses

Treprostinil is indicated for the treatment of pulmonary arterial hypertension in patients with NYHA Class II-IV symptoms to diminish symptoms associated with exercise. It may be administered as a continuous subcutaneous infusion or continuous intravenous infusion; however, because of the risks associated with chronic indwelling central venous catheters, including serious blood stream infections, continuous intravenous infusion should be reserved for patients who are intolerant of the subcutaneous route, or in whom these risks are considered warranted.

In patients with pulmonary arterial hypertension requiring transition from epoprostenol sodium (Flolan), treprostinil is indicated to diminish the rate of clinical deterioration. The risks and benefits of each drug should be carefully considered prior to transition.

There is a report that Treprostinil has improved signs and symptoms in Malignant Atrophic Papulosis.

Adverse affects

Since treprostinil is a vasodilator, its antihypertensive effect may be compounded by other medications that affect the blood pressure, including calcium channel blockers, diuretics, and other vasodilating agents.

Because of treprostinil’s inhibiting effect on platelet aggregation, there is an increased risk of bleeding, especially among patients who are also taking anticoagulants.

It is not known whether treprostinil is excreted in breast milk. Caution is advised when administering this medication to nursing women.

Caution is advised when administering treprostinil to patients who have impaired kidney or liver function.

Common side effects:

85% of patients report pain or other reaction at the infusion site. Other side effects may include headache, diarrhea, nausea, rash, jaw pain, vasodilatation, dizziness, edema (swelling), pruritus (itching), and hypotension.

Warnings:

Abrupt interruption of the treprostinil infusion can lead to worsening of pulmonary hypertension symptoms, and should be avoided.

Mechanism of action

The major effects of treprostinil are vasodilation of arteries in the pulmonary (lung) and body. Treprostinil also inhibitsplatelet aggregation.

Disclaimer:

Information on this page is provided for general information purposes. You should not make a clinical treatment decision based on information contained in this page without consulting other references including the package insert of the drug, textbooks and where relevant, expert opinion. We cannot be held responsible for any errors you make in administering drugs mentioned on this page, nor for use of any erroneous information contained on this page.